Functional characterization of 26 CYP2B6 allelic variants (CYP2B6.2-CYP2B6.28, except CYP2B6.22)

Pharmacogenetics and Genomics

Volumn 20, Issue 7, 2010, Pages 459-462

  Watanabe, Takashi ^a   Sakuyama, Kanako ^a   Sasaki, Takamitsu ^a   Ishii, Yuya ^a   Ishikawa, Masaaki ^a   Hirasawa, Noriyasu ^b   Hiratsuka, Masahiro ^b  

^a TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

Author keywords

7 ethoxy 4 trifluoromethylcoumarin; alleles; CYP2B6; cytochrome P450; genetic polymorphism; selegiline

Indexed keywords

7 ETHOXY 4 TRIFLUOROMETHYLCOUMARIN; COUMARIN DERIVATIVE; CYTOCHROME P450 2B6; SELEGILINE; UNCLASSIFIED DRUG; CYP2B6 PROTEIN, HUMAN; MUTANT PROTEIN; N DEMETHYLASE; UNSPECIFIC MONOOXYGENASE;

ALLELE; ANIMAL CELL; ARTICLE; CELL STRAIN COS7; CYP2B6 GENE; DEETHYLATION; DEMETHYLATION; DEPROPARGYLATION; DRUG METABOLISM; GENE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; WILD TYPE; ANIMAL; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; GENETICS; HUMAN; KINETICS;

ALLELES; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CERCOPITHECUS AETHIOPS; COS CELLS; CYTOCHROME P-450 CYP2B6; HUMANS; KINETICS; MUTANT PROTEINS; OXIDOREDUCTASES, N-DEMETHYLATING;

EID: 77953913990     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32833bba0e     Document Type: Article

References (10)

1. Lang T, Klein K, Richter T, Zibat A, Kerb R, Eichelbaum M, et al. Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J Pharmacol Exp Ther 2004; 311:34-43.
2. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U, et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001; 11:399-415.
3. Hiratsuka M, Hinai Y, Konno Y, Nozawa H, Konno S, Mizugaki M. Three novel single nucleotide polymorphisms (SNPs) of the CYP2B6 gene in Japanese individuals. Drug Metab Pharmacokinet 2004; 19:155-158.
4. Zanger UM, Klein K, Saussele T, Blievernicht J, Hofmann MH, Schwab M. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics 2007; 8:743-759.
5. Rotger M, Tegude H, Colombo S, Cavassini M, Furrer H, Decosterd L, et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther 2007; 81:557-566.
6. Wang J, Sonnerborg A, Rane A, Josephson F, Lundgren S, Stahle L, Ingelman-Sundberg M. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics 2006; 16:191-198.
7. Jinno H, Tanaka-Kagawa T, Ohno A, Makino Y, Matsushima E, Hanioka N, Ando M. Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab Dispos 2003; 31:398-403.
8. Klein K, Lang T, Saussele T, Barbosa-Sicard E, Schunck WH, Eichelbaum M, et al. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 2005; 15:861-873.
9. Morse MA, Lu J. High-performance liquid chromatographic method for measurement of cytochrome P450-mediated metabolism of 7-ethoxy-4- trifluoromethylcoumarin. J Chromatogr B Biomed Sci Appl 1998; 708:290-293.
10. Kamada T, Chow T, Hiroi T, Imaoka S, Morimoto K, Ohde H, Funae Y. Metabolism of selegiline hydrochloride, a selective monoamine b-type inhibitor, in human liver microsomes. Drug Metab Pharmacokinet 2002; 17:199-206.